[ad_1]
The Agreement Expands Options for Customers Seeking Cost-Effective, High-Throughput Whole Genome Sequencing
NEW YORK, June 2, 2022 /PRNewswire/ — Gencovepioneer of low-pass whole genome sequencing and analysis software, and Element Biosciences Inc., developer of the Element AVITI™ System, a new and disruptive DNA sequencing platform, today announced a joint marketing agreement to further reduce the cost and complexity of obtaining genomic information.
Whole genome sequencing provides a new foundation to advance healthcare, understand pathogens and feed our growing population. Combining the unrivaled performance and flexibility of the AVITI System with Gencove’s software platform democratizes access to genomic information.
Gencove’s…
Full story available on Benzinga.com
[ad_2]
Source link
